Phase I, Double-blind, Randomized, Placebo-controlled, Single Ascending Dose Study of Intravenous APL-9 in Healthy Volunteers
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 13 Jul 2018
At a glance
- Drugs APL 9 (Primary)
- Indications Paroxysmal nocturnal haemoglobinuria
- Focus Adverse reactions
- 09 Jul 2018 Status changed from recruiting to active, no longer recruiting.
- 30 May 2018 Planned number of patients changed from 24 to 30.
- 30 May 2018 Planned End Date changed from 8 May 2018 to 27 Jul 2018.